You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme

Article metrics

Article menu
XML
Immunology and inflammation
Original research
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme

 

Online download statistics by month:

Online download statistics by month: February 2021 to March 2024

AbstractFullPdf
Feb 2021385368125
Mar 2021288278102
Apr 202128728360
May 202112211532
Jun 2021959147
Jul 2021807932
Aug 2021868437
Sep 2021656427
Oct 2021767739
Nov 2021737344
Dec 2021717037
Jan 2022505532
Feb 2022342918
Mar 2022686546
Apr 2022798149
May 2022716932
Jun 2022524915
Jul 2022545628
Aug 2022454524
Sep 2022646929
Oct 2022555441
Nov 2022313127
Dec 2022272713
Jan 2023333330
Feb 2023777943
Mar 2023373731
Apr 2023353530
May 2023323222
Jun 2023414017
Jul 2023403921
Aug 2023363621
Sep 2023343322
Oct 202329285
Nov 2023393813
Dec 2023868617
Jan 2024292413
Feb 2024403623
Mar 2024555484
Total290128421328